Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome : A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial) by N. Kr&#246 et al.
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
Dose-Reduced Versus Standard Conditioning Followed by
Allogeneic Stem-Cell Transplantation for Patients With
Myelodysplastic Syndrome: A Prospective Randomized Phase
III Study of the EBMT (RICMAC Trial)
Nicolaus Kro¨ger, Simona Iacobelli, Georg-Nikolaus Franke, Uwe Platzbecker, Ruzena Uddin, Kai Hu¨bel, Christof
Scheid, Thomas Weber, Marie Robin, Matthias Stelljes, Boris Afanasyev, Dominik Heim, Giorgio Lambertenghi
Deliliers, Francesco Onida, Peter Dreger, Massimo Pini, Stefano Guidi, Liisa Volin, Andreas Gu¨nther, Wolfgang
Bethge, Xavier Poire´, Guido Kobbe, Marleen van Os, Ronald Brand, and Theo de Witte
A B S T R A C T
Purpose
To compare a reduced-intensity conditioning regimen (RIC) with a myeloablative conditioning
regimen (MAC) before allogeneic transplantation in patients with myelodysplastic syndrome (MDS)
within a randomized trial.
Patients and Methods
Within the European Society of Blood and Marrow Transplantation, we conducted a prospective, mul-
ticenter, open-label, randomized phase III trial that compared a busulfan-based RIC with MAC in patients
with MDS or secondary acute myeloid leukemia. A total of 129 patients were enrolled from 18 centers.
Patientswere randomly assigned in a 1:1 ratio andwere stratified according to donor, age, and blast count.
Results
Engraftment was comparable between both groups. The CI of acute graft-versus-host disease II
to IV was 32.3% after RIC and 37.5% after MAC (P = .35). The CI of chronic graft-versus-host
disease was 61.6% after RIC and 64.7% after MAC (P = .76). The CI of nonrelapse mortality after
1 year was 17% (95%CI, 8% to 26%) after RIC and 25% (95%CI, 15% to 36%) after MAC (P = .29).
The CI of relapse at 2 years was 17% (95%CI, 8% to 26%) after RIC and 15% (95%CI, 6% to 24%)
after MAC (P = .6), which resulted in a 2-year relapse-free survival and overall survival of 62% (95%
CI, 50% to 74%) and 76% (95%CI, 66% to 87%), respectively, after RIC, and 58% (95%CI, 46% to
71%) and 63% (95% CI, 51% to 75%), respectively, after MAC (P = .58 and P = .08, respectively).
Conclusion
This prospective, randomized trial of the European Society of Blood and Marrow Transplantation
provides evidence that RIC resulted in at least a 2-year relapse-free survival and overall survival
similar to MAC in patients with MDS or secondary acute myeloid leukemia.
J Clin Oncol 35:2157-2164. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Myelodysplastic syndromes (MDS) are a hetero-
geneous group of clonal hematopoietic disorders
that are characterized by abnormal cellular
maturation that results in cytopenias and variable
risk of progression to acute leukemia.1 Recently,
new insights into the biology of this disease
have helped to understand its pathophysiology,
and new drugs, such as hypomethylating agents,
have been shown to prolong survival2; however,
allogeneic stem-cell transplantation from HLA-
compatible donors is still the treatment with
the highest chance of cure, and the number of
transplantations is steadily increasing, especially
in older patients.3-6 This is primarily a result of
increasing donor availability and the introduc-
tion of reduced-intensity conditioning regimens
(RICs).7 Several retrospective studies from the
European Group of Blood and Marrow Trans-
plantation (EBMT) as well as larger centers have
reported a higher risk of relapse but a lower rate
of nonrelapse mortality (NRM) when compar-
ing RIC with myeloablative conditioning regi-
mens (MACs), which has resulted in comparable
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survival after both approaches.8-10 However, in all studies, the
patient age was significantly higher in the RIC arm and smaller
studies reported no difference in relapse rate if patients underwent
transplantation in complete remission without active disease.11
To circumvent selection bias, we performed a prospective,
multicenter, open-label phase III study comparing a busulfan-
based standard myeloablative conditioning regimen with a busul-
fan-based RIC regimen in patients with MDS or secondary acute
myeloid leukemia (sAML) and , 20% blasts (RICMAC Study).
PATIENTS AND METHODS
Patient Characteristics
In this prospective, multicenter, open-label randomized phase III
study, patients were randomly assigned to receive a myeloablative con-
ditioning regimen that consisted of busulfan (16 mg/kg orally or 12.8 mg/
kg intravenously) and cyclophosphamide (120 mg/kg) or a an RIC regimen
that consisted of busulfan (8 mg/kg orally or 6.4 mg/kg intravenously) and
fludarabine (150 mg/m2) followed by allogeneic stem-cell transplantation
from a related or unrelated donor. Detailed characteristics of patients are
listed in Table 1.
Major inclusion criteria were cytologically proven MDS and sAML
with , 20% of blasts at time of transplantation, a matched related or
unrelated donor (one mismatch was allowed), age 18 to 60 years for un-
related donors and age 50 to 65 years for related donors, which was amended
in 02/2006 to age 18 to 65 years. Eighty-five percent of chemotherapies
before transplantation were administered in advanced MDS (chronic
myelomonocytic leukemia, refractory anemia with excess of blasts, and
sAML) to reduce the number of blasts (85%), whereas only 15% of che-
motherapies were administered to less advanced MDS (refractory anemia,
refractory anemia with ringsideroblasts, and refractory anemia with mul-
tilineage dysplasia). Other inclusion criteria were adequate hepatic, renal,
pulmonary, and cardiac functions. Graft-versus-host disease (GVHD)
prophylaxis consisted of cyclosporine and a short course of methotrexate
(10 mg/m2 on days +1, +3, +6, and +11) for both arms. In the case of
unrelated donor antilymphocyte globulin (Fresenius, Graefelfing, Germany)
at a cumulative does of 30 to 60 mg/kg or antithymocyte globulin
(Thymoglobulin; Sanofi, Paris, France) at a cumulative dose of 6 to 10mg/kg
could be administered divided on days 23, 22, and 21 or alemtuzumab
100 mg divided on days 28 to 24 according to center policy; however,
alemtuzumab was not used in a single patient.
Supportive Care
Cyclosporine A dose was adjusted to a whole-blood level between 200
and 300 mg/L and should be tapered from day +120 to be discontinued at
day +180. All patients received fluconazole or other antifungal prophylaxis
according to local policy. Antibacterial prophylaxis consisted of ofloxacin
or ciprofloxacin and antiviral prophylaxis of acyclovir. Cytomegalovirus
(CMV) reactivation was treated pre-emptively with ganciclovir or
foscarnet. Further anti-infective prophylaxis consisted of twice weekly
cotrimoxazole or monthly inhalation with pentamidine. Blood products
were administered according to local policy. Epstein-Barr virus reac-
tivation was defined as positive DNA assay on whole blood or plasma,
according to center policy. CMV reactivation was defined as positive CMV
pp65 antigenemia and/or DNA assay.
The primary end point of the study was NRM after 1 year. Secondary
end points were comparison of engraftment, toxicity, acute and chronic
GVHD, infectious complications, and event-free survival and overall
survival at 2 years.
Acute GVHD was scored according to Glucksberg,12 whereas chronic
GVHDwas scored according to Shulman criteria (limited and extensive).13
The RICMAC Study was conducted in accordance with good clinical
practice guidelines and the provisions of the Declaration of Helsinki. Protocol
Table 1. Patient Characteristics
Characteristic
Standard
Conditioning,
No. (n = 64)
Reduced-Intensity
Conditioning,
No. (n = 65) P
Age, years .874
Median (range) 50 (19-64) 51 (22-63)
# 45 15 15
46-50 17 16
51-55 10 17
56-60 19 13
61-65 3 4
Diagnosis according
to WHO
.569*
5q 0 2
CMML 3 3
MDS unclassifiable 2 3
RA 4 3
RARS 5 3
RAEB-1 12 19
RAEB-2 15 17
RCMD 12 8
RCMD-RS 1 3
sAML 8 4
Missing 2
Prior induction
chemotherapy
.253
No 33 40
Yes 31 25
Donor .962
Matched related 17 16
Matched unrelated 36 38
Mismatch unrelated/
related
11 11
ATG as GVHD prophylaxis .791
No 31 33
Yes 33 32
Blasts at transplantation .034
Median (range) 4% (0-18) 5% (0-18)
. 5% 18 30
# 5% 46 35
Recipient sex .916
Male 38 8
Female 26 27
Donor sex .846
Male 40 43
Female 22 22
Missing 2
Gender mismatch .285
Male/female 9 14
Others 53 51
Missing 2
Recipient/donor CMV
constellation
.250
Negative/negative 28 21
Positive/negative 12 9
Negative/positive 10 9
Positive/positive 14 24
Missing 2
IPSS at diagnosis .737*
Low risk 2
Intermediate I 28 25
Intermediate II 18 24
High risk 9 7
Missing 7 7
Cytogenetic risk .650
Low 24 28
Intermediate 17 13
High 17 18
Missing 6 6
(continued on following page)
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approval was obtained from an independent ethics committee at each study site.
All patients provided written informed consent. EBMT sponsored the study.
Statistical Methods
The study planned to enroll 160 patients to detect a difference in
1-year treatment-related mortality of 40% after MAC versus 20% after RIC
with a power of 90% and a significance level of 5% in a two-sided test using
a proportional hazards model. As a result of a slow accrual rate, inclusion
stopped when 129 patients were enrolled. At that moment, a blinded power
calculation on the basis of the same hypotheses on expected NRM rates and
in various likely scenarios for relapse rate returned power superior to 80%
with a sample size of 120 patients. It was thus considered appropriate to
stop the accrual and proceed with the final analysis. This showed, however,
actual NRM rates lower than expected, in particular, in theMAC arm; thus,
the study was underpowered (, 35%) to detect a true difference in NRM
that was equal to the observed difference.
Therapy-related mortality—NRM— and relapse were analyzed in
a competing risks framework by using the cumulative incidence estimator and
the Gray test for univariable analysis as well as Cox proportional hazards re-
gression for analysis of cause-specific hazards. Overall survival and relapse-free
survival were estimated by using the Kaplan-Meier method and compared with
the Log-Rank test in univariable analysis, and by Cox proportional hazards
regression in multivariable analysis. Stratification factors (donor type, blasts,
age) as well as patient and donor gender or gender mismatch, CMV status
combination, diagnosis subgroup (sAML v other), cytogenetics, International
Prognostic Scoring System score, performance status, prior chemotherapy, and
use of busulfan were considered for inclusion in Cox models with the random
assignment arm. Selection was done on the basis of significance, taking into
account prior clinical knowledge, the presence of missing values, and aspects
related to model validation. Cases with missing values for one variable were
excluded, but we confirmed the robustness of the results when including the
missing variable as a further level. The proportional hazards assumption in Cox
models was assessed by analysis of scaled Schoenfeld residuals, and no relevant
departure was detected. The study was not specifically powered to investigate
interactions and perform subgroup analyses. Following protocol, subgroup
analyses were performed when the corresponding interaction term with the
random assignment armwas found to be significant at the 10% level in the Cox
proportional hazards regression model.
Acute and chronic GVHD were assessed by using the crude cu-
mulative incidence estimator and the Gray test considering relapse and
death as competing risks. Incidences of infections were estimated in terms
of rates (for 100 person-years), and a Poisson-based exact method was used
for testing rate ratios. Occurrence of serious adverse events as well as
categorical characteristics were compared by x2 or Fisher’s exact test, and
the Mann-Whitney test was used for continuous variables.
All end points were analyzed including all randomly assigned patients
grouped according to random assignment arm, except secondary safety
end points, which were analyzed in the subpopulation of patients who were
treated according to protocol (n = 125; Fig 1). Following study protocol
that required a follow-up of 2 years, all end points were artificially censored
at 24 months. Curves are not displayed beyond this time because only
a minority of patients had longer follow-up.
Analyses were performed by using SPSS for Windows version 23
(SPSS, Chicago, IL) and R package version 3.1.0 (The R Foundation,
Vienna, Austria; libraries survival, prodlim, cmprsk, and exactci).
Random Assignment Procedure
Patients were randomly assigned in a 1:1 ratio and stratified according
to donor (related v unrelated) blasts (, 5% or. 5%) and age (, 45 years
or . 45 years). Patient flow is shown in Fig 2.
RESULTS
Patients and Treatment
Between May 2004 and December 2012, a total of 129 patients
were enrolled in 18 centers and seven countries. Baseline charac-
teristics of the remaining 129 patients were well balanced (Table 1).
Graft Failure and Engraftment
Four and three graft failures occurred after standard and RIC
regimens, respectively (P = .72). Median time for leukocyte en-
graftment (absolute neutrophil count $ 0.5 3 109/L) was 15 days
in each arm, and for platelet ($ 50 3 109/L) engraftment, 15 days
(range, 4 to 158 days) in the RIC arm versus 16 days (range, 10 to
185 days) in the standard arm (P = .33; Table 2).
Acute and Chronic GVHD
Cumulative incidence of acute GVHD grade II to IVand grade
III and IV was 32.3% and 15% in the RIC arm, respectively, and
37.5% and 14% in the standard arm, respectively (P = .35; Table 2).
The CI of chronic GVHD at 24 months was 61.6% (95% CI, 48.9%
to 74.3%) in the RIC arm and 64.7% (95% CI, 51.3% to 78.1%) in
the standard arm (P = .76).
Toxicity and NRM
Infectious complications were more frequently observed in
the standard arm (rate in 100 patient-years at day 100, 6.9 v 4.3;
P = .002). There was no difference in CMV reactivation, EBV
reactivation, or other viral or fungal infection (Table 2). Veno-
occlusive disease was reported in four patients in theMAC arm and
no patients in the RIC arm, but no patient died of veno-occlusive
disease. NRMs at 1 year was 16.9% (95% CI, 7.8% to 26.0%) in the
RIC arm and 25.3% (95% CI, 14.6% to 36%) in the standard arm
(P = .29; Table 2 and Fig 2A).
Table 1. Patient Characteristics (continued)
Characteristic
Standard
Conditioning,
No. (n = 64)
Reduced-Intensity
Conditioning,
No. (n = 65) P
ECOG performance
status at diagnosis
.692*
0 18 21
1 32 29
2 3 3
3 0 2
Missing 11 10
Busulfan .053
Intravenously 47 38
Orally 16 27
Missing 1 0
Stem cell source .311
Bone marrow 3 6
PBSC 61 59
Abbreviations: ATG, antilymphocyte globulin; CMML, chronic myelomonocytic
leukemia; CMV, cytomegalovirus; ECOG, Eastern Cooperative Oncology Group;
GVHD, graft-versus-host disease; IPSS, International Prognostic Scoring Sys-
tem; MDS, myelodysplastic syndrome; PBSC, peripheral blood stem cell; RA,
refractory anemia; RAEB, refractory anemia with excess of blasts; RARS, re-
fractory anemia with ringsideroblasts; RCMD, refractory anemia with multi-
lineage dysplasia; sAML, secondary acute myeloid leukemia.
*Diagnosis: RAEB-1/RAEB-2/sAML/CMML v other; IPSS at diagnosis: low-
intermedia I v intermediate II v high; ECOG performance status, 0 v 1-3.
jco.org © 2017 by American Society of Clinical Oncology 2159
RIC v MAC in MDS
Downloaded from ascopubs.org by Malliani on October 5, 2017 from 159.149.193.159
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Organ toxicity according to Bearman’s score did not differ,
apart from stomatitis, which was significantly lower in the RIC arm
(P = .05; Appendix Tables A1 and A2, online only)
Relapse
The CI of relapse at 2 years was 17.0% (95% CI, 7.9% to
26.2%) in the RIC arm and 14.8% (95% CI, 5.8% to 23.7%) in the
standard arm (P = .64; Table 2 and Fig 2B).
Survival
The 2-year relapse-free survival was 62.4% (95% CI, 50.4% to
74.4%) in the RIC arm and 58.3% (95%CI, 46.0% to 70.6%) in the
standard arm (P= .58), and 2-year overall survival was 76.3% (95%
CI, 65.8% to 86.9%) after RIC versus 63.2% (95% CI, 51.1% to
75.2%) after standard conditioning, respectively (P = .08; Table 2
and Figs 2C and 2D).
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Fig 1. (A–D) Nonrelapse mortality (A), relapse incidence (B), relapse-free survival (C), and overall survival (D) according to intensity of conditioning regimen. MAC,
myeloablative conditioning; RIC, reduced-intensity conditioning.
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Multivariable and Subgroup Analyses
In a multivariable analysis (MVA), NRM was influenced by
performance status (Eastern Cooperative Oncology Group per-
formance status . 0: hazard ratio [HR], 3.68; 95% CI, 1.26 to
10.76; P = .02) and cytogenetic risk (HR low v intermediate, 5.63;
95% CI, 1.28 to 24.82; P = .02; HR high v intermediate, 4.28; 95%
CI, 0.91 to 20.19; P = .07), whereas for RIC, only a trend for lower
NRM was noted (HR, 0.63; 95% CI, 0.28 to 1.40; P = .26; Table 3).
In the model of NRM, an interaction was found between the
random assignment arm and cytogenetics (P = .08), which led to
a subgroup analysis stratified by cytogenetics risk group. In the
low-risk group, the RIC arm resulted in lower NRM (HR, 0.30;
95% CI, 0.10 to 0.89; P = .03). In the intermediate- and high-risk
cytogenetic groups, RIC resulted in a higher NRM (HR, 1.17; 95%
CI, 0.07 to 18.83; P = .9; and HR, 2.14; 95% CI, 0.51 to 9.00; P = .3,
respectively). A conclusive answer for this observation cannot be
given, but a possible explanation would be that low-risk patients
are protected from relapse and are thus more at risk for death
without relapse. No other interaction was found.
In an MVA for relapse, advanced disease resulted in a higher
risk (HR, 13.26; 95% CI, 1.77 to 99.14; P = .01), whereas RIC had
an HR of only 1.05 (95% CI, 0.44 to 2.54; P = .9). Advanced disease
was also a significant risk factor for lower relapse-free survival (HR,
2.77; 95% CI, 1.30 to 5.91; P = .008), whereas RIC was not (HR,
1.05; 95% CI, 0.44 to 2.54; P = .9). In an MVA for overall survival,
worse survival was noted for low versus intermediate cytogenetic
risk (HR, 6.06; 95% CI, 1.69 to 21.80; P = .005), for high versus
intermediate cytogenetic risk (HR, 4.51; 95% CI, 1.28 to 15.86;
P = .02), and for advanced disease (HR, 2.26; 95% CI, 0.95 to 5.39;
P = .06), whereas RIC resulted in improved overall survival (HR,
0.41; 95% CI, 0.19 to 0.87; P = .02).
DISCUSSION
In this prospective, multicenter, multinational phase III study of
the EBMT RIC regimen, administration before allogeneic stem-cell
transplantation in patients with MDS was at least equivalent to the
results after treatment with a standard myeloablative conditioning
regimen. The CI of relapse at 2 years was nearly identical in-
dependent of conditioning regimen intensity, whereas NRM
tended to be higher after myeloablative conditioning, although not
significantly. The only risk factor for relapse in a multivariable
analysis was advanced disease status, which was defined as CMML,
RAEB, or sAML.
The role of conditioning regimen intensity before allogeneic
stem-cell transplantation for MDS has not been studied pro-
spectively and recommendations are based on retrospective single-
center or registry studies.8,10 Despite this lack of evidence, the
European Leukemia Net recommended a standard myeloablative
Table 2. Results
Standard Conditioning
Reduced-Intensity
Conditioning P
Graft failure 4 3 .72
Median time for leukocytes . 1.0 3 109/L
(range), days
15 (9-32) 15 (4-25) .81
Median time for platelets . 50 3 109/L
(range), days
16 (10-185) 15 (4-158) .33
Acute GVHD, No. (%) .35
Grade 1 8 (13) 13 (20)
Grade 2 15 (23) 11 (17)
Grade 3 6 (9) 9 (14)
Grade 4 3 (5) 1 (1)
Chronic GVHD, No. (%) .76
Limited 11 (22) 13 (23)
Extensive 21 (41) 25 (44)
Overall No. of infections 48 44
Rate (per 100 person-years) day 1-100 6.9 (5.7-8.4) 4.3 (3.4-5.4) .002
Rate (per 100 person-years) total follow-up 2.0 (1.7-2.3) 1.4 (1.2-1.6) .002
Overall No. of bacterial infections 31 22
Rate (per 100 person-years) day 1-100 2.3 (1.6-3.2) 1.3 (0.8-1.9) .029
Rate (per 100 person-years) total follow-up 0.6 (0.4-0.8) 0.4 (0.3-0.5) .133
Overall No. of CMV reactivation, No. 12 18 .17
Overall No. of EBV reactivation, No. 8 11 .49
Overall No. of viral infections, No. 21 14 .24
No. of bacterial infections until day 100, No. 28 17 .03
Number of fungal infections until day 100, No. 11 8 .53
Nonrelapse mortality at 1 year, % (95% CI) 25.3 (14.6 to 36.0) 16.9 (7.8 to 26.0) .29
Relapse incidence at 2 years, % (95% CI) 14.8 (5.8 to 23.7) 17.0 (7.9 to 26.2) .64
Relapse-free survival at 2 years, % (95% CI) 58.3 (46.0 to 70.6) 62.4 (50.4 to 74.4) .58
Overall survival at 2 years, % (95% CI) 63.2 (51.1 to 75.2) 76.3 (65.8 to 86.9) .08
Cause of death .18
Disease related 5 2
Transplant related 18 11
Other 0 2
Abbreviations: CMV, cytomegalovirus; EBV, Epstein-Barr virus; GVHD, graft-versus-host disease.
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conditioning regimen for all patients without comorbidities. Those
patients with comorbidities should receive RIC, preferably within
a clinical trial.1 The rationale for using RIC before allogeneic stem-
cell transplantation is to shift from high-dose chemotherapy that
is aimed at maximizing cytotoxic leukemia killing to a more
immune-mediated effect by harvesting the graft-versus-tumor
effect to eradicate the disease. Retrospective registry studies have
suggested a low risk of NRM but a higher risk of relapse after RIC;
however, patients who received RIC were older than those who
received standard myeloablative conditioning.4,8 To avoid selection
bias in the study, all patients should have been eligible for standard
myeloablative conditioning at the time of study inclusion; however,
enrollment in the study was rather slow, which may be a result of
the strict inclusion criteria for age and also because of patients
declining to be randomly assigned and physician concern, because
several retrospective studies suggested a higher risk of relapse after
RIC; therefore, selection bias cannot be excluded. RIC is thought to
result in lower toxicity and lower mortality. Regarding toxicity, we
noted only significantly less stomatitis, which resulted only in
a trend for a lower NRM. Because mismatch unrelated donors were
included in this study, the NRM of MAC was surprisingly low and
the observed 25% NRM was much lower than the hypothesized
40% in the study protocol. A higher number of infections—mainly
of bacterial origin—was observed after MAC conditioning. An-
other unexpected result was the higher NRM for the low-risk
cytogenetic group compared with intermediate cytogenetic risk. In
a nonpowered subanalysis for NRM, RIC in the low-risk group
resulted in lower NRM. In the intermediate- and high-risk cy-
togenetic groups, RIC resulted in a higher but nonsignificant
NRM. Our analysis is not conclusive regarding the role of RIC in
the high-risk group. Advanced disease is a significant factor for
relapse-free survival and overall survival, but our study protocol
did not allow subgroup analyses if interaction was P . .1.
In a multivariate analysis for overall survival, RIC resulted
in a significant survival benefit at 2 years. Improved survival
after RIC might be a result of lower mortality after relapse.
Whereas after MAC six of nine patients who experienced relapse
died, in the RIC arm, only two of 11 patients who experienced
relapse died.
Whereas retrospective studies suggest a higher risk of relapse
but a lower NRM after RIC, there are few available prospective
studies that show similar survival rates. These studies, however,
included mainly or only patients with AML who may differ in
outcome from patients with MDS. In a German multicenter study,
patients with AML in 1. Complete remission reduced-intensity
total body irradiation–based conditioning regimen resulted in no
significant difference in NRM, relapse incidence, and disease-free
survival and overall survival compared with a standard myeloa-
blative conditioning regimen.14
In older patients with AML who were in remission, a busul-
fan-based RIC regimen resulted in a lower NRM but similar overall
survival.15 These trials, however, included only patients with AML.
A recent multicenter US trial that compared RIC versus mye-
loablative conditioning and that included patients with AML and
MDSwas closed prematurely because of inferior outcome after RIC
(BMT-CTN 0901 trial); however, the superior effect for survival of
myeloablative conditioning was seen observed in patients with
AML but not in those with MDS.16 Whereas in recent years the
RIC arm
Follow-up
Analysis
Enrolled patients
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   Age violation
    (Two patients too young, one too old)
(N = 129)
 (n = 4)
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Fig 2. Flow diagram of the study. Four patients deviated from the inclusion criteria: one patient had twomismatches in HLA between patient and donor, one patient was
too old, and two patients where too young. The lower level for age inclusion was amended during the recruitment phase from age 50 years to age 18 years—because of
a competing European Group of Blood andMarrow Transplantationmyelodysplastic syndrome trial, age inclusion for patients with related donor was restricted to age 50 to
65 years at first; when the competing trial stopped, age inclusion was amended. Both patients that were too young (age 43 and 48 years) at time of registration did fulfill
these extended inclusion criteria; therefore, these two patients are included in both the intention-to-treat analysis as well as the per-protocol analysis. There are four
patients who were excluded from the per-protocol analysis: The patient who was too old (this patient was treated with total body irradiation/fludarabine [TBI/Flu]). The
patient who had two mismatches and the two patients who were treated with reduced-intensity conditioning (RIC) regimen in the myeloablative conditioning (MAC) arm.
The patient who was treated with tacrolimus instead of cyclosporine A (CsA) was included in both the intention-to-treat analysis and the per protocol analysis.
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number of allogeneic stem-cell transplantation for older patients
with MDS have increased,3 in our study, the majority of patients
were age , 60 years, because the upper age limit in the study was
age 60 years for unrelated donor and age 65 years for related donor.
In summary, our study shows that RIC and MAC followed by
allogeneic stem-cell transplantation resulted in at least an equiv-
alent survival trend for a better 2-year overall survival, especially in
the cytogenetic low-risk group and can be offered as an alternative
to a myeloablative regimen.
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Table 3. Multivariable Analysis
Parameter HR (95% CI) P
Nonrelapse mortality
RIC 0.63 (0.28 to 1.40) .26
Cytogenetics .02
Low risk 5.63 (1.28 to 24.82) .02
High risk 4.28 (0.91 to 20.19) .07
ECOG . 0 3.68 (1.26 to 10.76) .02
Relapse
RIC 1.05 (0.44 to 2.54) .91
Advanced disease 13.26(1.77 to 99.14) .01
Relapse-free survival
RIC 0.76 (0.42 to 1.38) .36
Advanced disease 2.77 (1.30 to 5.91) .008
Overall survival
RIC 0.41 (0.19 to 0.87) .02
Cytogenetics , .001
Low risk 6.06 (1.69 to 21.80) .005
High risk 4.51 (1.28 to 15.86) .02
ECOG . 0 2.32 (0.99 to 5.43) .05
Advanced disease 2.26 (0.95 to 5.39) .06
NOTE. In the model of nonrelapse mortality (NRM), an interaction was found
between the random assignment arm and cytogenetics (P = .08), which led to
a subgroup analysis stratified by cytogenetics risk group. In the low-risk group,
lower performance status (ECOG . 0: HR, 2.65; 95% CI, 0.74 to 9.47; P = .13)
influenced NRM,whereas the RIC arm resulted in lower NRM (HR, 0.30; 95%CI,
0.10 to 0.89; P = .03). In the intermediate- and high-risk cytogenetic groups, RIC
resulted in a higher NRM (HR, 1.17; 95% CI, 0.07 to 18.83; P = .9; and HR, 2.14;
95% CI, 0.51 to 9.00; P = .3, respectively).
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio;
RIC, reduced-intensity conditioning.
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Appendix
Table A1. Safety Statistics (per-protocol population)
Parameter
Random Assignment Arm
0 MAC,
No. (%)
1 RIC, No.
(%)
Total,
No. (%)
max bearman
0: no or grade 1 8 (17.0) 15 (32.6) 23 (24.7)
1: 2 or higher 39 (83.0) 31 (67.4) 70 (75.3)
Total 47 (100.0) 46 (100.0) 93 (100.0)
cardiac_grade
.00: no or grade 1 43 (91.5) 44 (97.8) 87 (94.6)
1.00: 2 or higher 4 (8.5) 1 (2.2) 5 (5.4)
Total 47 (100.0) 45 (100.0) 92 (100.0)
bladder_grade
.00: no or grade 1 46 (97.9) 45 (100.0) 91 (98.9)
1.00: 2 or higher 1 (2.1) 0 (0.0) 1 (1.1)
Total 47 (100.0) 45 (100.0) 92 (100.0)
renal_grade
.00: no or grade 1 38 (80.9) 41 (91.1) 79 (85.9)
1.00: 2 or higher 9 (19.1) 4 (8.9) 13 (14.1)
Total 47 (100.0) 45 (100.0) 92 (100.0)
pulmonary_grade
.00: no or grade 1 43 (91.5) 43 (95.6) 86 (93.5)
1.00: 2 or higher 4 (8.5) 2 (4.4) 6 (6.5)
Total 47 (100.0) 45 (100.0) 92 (100.0)
hepatic_grade
.00: no or grade 1 36 (76.6) 38 (84.4) 74 (80.4)
1.00: 2 or higher 11 (23.4) 7 (15.6) 18 (19.6)
Total 47 (100.0) 45 (100.0) 92 (100.0)
cns_grade
.00: no or grade 1 46 (97.9) 43 (95.6) 89 (96.7)
1.00: 2 or higher 1 (2.1) 2 (4.4) 3 (3.3)
Total 47 (100.0) 45 (100.0) 92 (100.0)
stomatitis_grade
.00: no or grade 1 13 (27.7) 22 (48.9) 35 (38.0)
1.00: 2 or higher 34 (72.3) 23 (51.1) 57 (62.0)
Total 47 (100.0) 45 (100.0) 92 (100.0)
gi_grade
.00: no or grade 1 46 (97.9) 43 (95.6) 89 (96.7)
1.00: 2 or higher 1 (2.1) 2 (4.4) 3 (3.3)
Total 47 (100.0) 45 (100.0) 92 (100.0)
NOTE. Bearman grades are recoded as 0 = no event or grade 1 v 1 = grade 2 or
higher.
Table A2. Tests for Significance
Parameter x2 Test Fisher’s Exact Test
max Bearman 0.082 0.097
cardiac_grade 0.184* 0.362
bladder_grade 0.325*† 1.000
renal_grade 0.158* 0.232
pulmonary_grade 0.430* 0.677
hepatic_grade 0.343 0.434
cns_grade 0.532* 0.613
stomatitis_grade 0.036 0.053
gi_grade 0.532* 0.613
NOTE. Because of the small numbers, the x2 test can be invalid, in which case
Fisher’s exact test is more appropriate.
*More than 20% of cells in this table have expected cell counts, 5. x2 results
may be invalid.
†Theminimum expected cell count in this table is, 1. x2 results may be invalid.
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